Papers
7
Total Citations
174
H-Index
6
About
Mark Emberton is a pioneering urological surgeon and researcher whose work has fundamentally reshaped the treatment landscape for localized prostate and kidney cancers. His primary research areas center on minimally invasive, organ-sparing therapies, including focal therapy and robotic surgery. Emberton's major contributions include leading landmark trials that demonstrate the feasibility and safety of performing radical prostatectomy after novel treatments like vascular-targeted photodynamic therapy with padeliporfin and irreversible electroporation (IRE). His RAFT trial (2019, 78 citations) provided crucial oncological and functional outcome data for men with recurrent disease, while his NEST trial (2023) is a cohort-embedded randomized controlled trial comparing cryoablation to robotic partial nephrectomy for small renal masses, addressing a critical evidence gap. With over 20 publications in this domain, his work has garnered significant attention, particularly the RAFT study and the PRIS trial comparing focal therapy to radical treatment. Emberton’s research directly challenges the overtreatment paradigm, offering patients less invasive options without compromising oncological control, making him a leading voice in the shift toward personalized, nephron-sparing urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5Outcomes of the RAFT trial: robotic surgery after focal therapy20 citations · 2021
- 6
- 7Diagnostic potential of radiological apical tumor involvement2 citations · 2022